更新于：2024-09-19

Myositis, Inclusion Body

包涵体肌炎

更新于：2024-09-19

基本信息

别名

IBM、IBM - Inclusion body myositis、INCLUSION BODY MYOSITIS

+ [27]

简介

Progressive myopathies characterized by the presence of inclusion bodies on muscle biopsy. Sporadic and hereditary forms have been described. The sporadic form is an acquired, adult-onset inflammatory vacuolar myopathy affecting proximal and distal muscles. Familial forms usually begin in childhood and lack inflammatory changes. Both forms feature intracytoplasmic and intranuclear inclusions in muscle tissue. (Adams et al., Principles of Neurology, 6th ed, pp1409-10)

关联

项与包涵体肌炎相关的药物

Arimoclomol Maleate

靶点-

作用机制

伴侣蛋白调节剂 [+1]

在研机构

Zevra Therapeutics, Inc.

原研机构

Orphazyme A/S

在研适应症

C型尼曼匹克病

非在研适应症

肌萎缩侧索硬化 [+3]

最高研发阶段申请上市

首次获批国家/地区-

首次获批日期1800-01-20

Garetosmab

加托索单抗

靶点

ALK2

作用机制

ALK2抑制剂

在研机构

Regeneron Pharmaceuticals, Inc.

原研机构

Regeneron Pharmaceuticals, Inc.

在研适应症

骨化性肌炎 [+1]

非在研适应症

包涵体肌炎 [+1]

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期1800-01-20

Ulviprubart

靶点

KLRG1

作用机制

KLRG1抑制剂

在研机构

Abcuro, Inc.初创企业

原研机构

Abcuro, Inc.初创企业

在研适应症

包涵体肌炎 [+1]

非在研适应症-

最高研发阶段临床2/3期

首次获批国家/地区-

首次获批日期1800-01-20

项与包涵体肌炎相关的临床试验

NCT06153108 / RecruitingN/AIIT

Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time

Inclusion-Body Myositis (IBM) results in weakness and the deterioration of distal arm muscles, the symptoms of which are currently assessed through expert examination at clinical visits. Such in-clinic assessments are time-consuming, subjective, of limited sensitivity, and only provide a snapshot of a patient's disease. In this project, we will conduct clinical validation of monitoring digital biomarkers of upper limb function during activities of daily living using a wearable sensor platform that enables frequent, at-home monitoring of upper limb function health in IBM and could be incorporated into IBM trials.

开始日期2023-11-16

申办/合作机构

University of Kansas Medical Center

[+1]

NCT05890833 / RecruitingN/A

The FBIndex to Determine the Risk of Falls and Its Translation to Assistive Gait Device Care for Patients With Neuromuscular Disorders

The combination of short quantitatively assessing muscular function and balance in combination with short clinical scores, can be a new valid approach to evaluate the patient risk of fall and help to create a quick checkup test to prescribe an appropriate assistive device.
The primary goal of this project is to provide a short battery of clinical assessments used to determine risk of falling for patients with neuromuscular diseases (NMD) based on correlation between clinical assessments between two groups of NMD patients and scales used to assess risk of falling for patients.

开始日期2023-09-01

申办/合作机构

University Hospital of Ludwig-Maximilians-University

NCT05721573 / Active, not recruiting临床2/3期

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body Myositis

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

开始日期2023-02-28

申办/合作机构

Abcuro, Inc.初创企业

[+1]

100 项与包涵体肌炎相关的临床结果

登录后查看更多信息

100 项与包涵体肌炎相关的转化医学

登录后查看更多信息

0 项与包涵体肌炎相关的专利（医药）

登录后查看更多信息

2,193

项与包涵体肌炎相关的文献（医药）

2024-02-16·Clinical and experimental rheumatology

Imaging swallowing function and the mechanisms driving dysphagia in inclusion body myositis.

Review

作者: Sharfaraz Salam ; Jodi Allen ; Mazen M Dimachkie ; Michael G Hanna ; Pedro M Machado

Sporadic inclusion body myositis (IBM) is a progressive condition which commonly affects patients aged above 40. IBM does not respond to immunosuppression and no proven treatments are available. Up to 80% of patients develop some degree of swallowing impairment during the disease course. Dysphagia is a source of marked morbidity in IBM and predisposes patients to life-threatening complications such as aspiration pneumonia. The pathophysiology behind dysphagia in IBM is not fully understood. Evidence from imaging demonstrates that impaired swallowing is predominantly underpinned by oropharyngeal deficits. Changes in cricopharyngeal physiology is thought to be an important factor influencing dysphagia in IBM. However, it is unclear whether this is secondary to structural changes within the cricopharyngeus itself or driven by impairment of the muscles promoting pharyngeal clearance. The approach to dysphagia in IBM patients is limited by a lack of validated instruments to reliably assess swallowing function and an absence of effective therapeutic interventions derived from controlled trials targeting dysphagia. Imaging modalities such as the video fluoroscopic swallowing study (VFSS) are commonly used to evaluate dysphagia in IBM. Whilst VFSS is a commonly used technique in clinical practice; cumulative radiation exposure with repeated testing can be a limitation. Alternative imaging techniques could be developed further as outcome measures for assessing swallowing.In this review, we provide an overview of imaging techniques used to assess swallowing and the insight provided from such investigations into the mechanisms behind dysphagia in IBM. We suggest future directions for evaluation and outcome measurement of dysphagia in this population.

2024-02-02·Ophthalmic plastic and reconstructive surgery

Bilateral Facial Palsy: A Rare Presenting Symptom for Inclusion Body Myositis.

Article

作者: Elana Meer ; Meleha Ahmad ; Seanna Grob ; Bryan J Winn

Inclusion body myositis is a common type of inflammatory myopathy among populations over the age of 50 years, classically presenting with weakness and atrophy of the forearms and quadriceps. While a third of patients may eventually present with mild facial weakness, findings of ptosis, facial palsy, or involvement of extraocular muscles are rarely, if ever, seen. The authors describe a unique case of inclusion body myositis in which a patient initially presented with bilateral severe facial palsy and exposure keratitis but minimal limb weakness. While midface weakness, unilateral lagophthalmos, and ptosis have been documented in one reported case, key presenting symptoms of bilateral facial palsy and symmetric paralytic lagophthalmos with corneal exposure have not been presented before. Therefore, this case serves as an important reminder to consider the inclusion body myositis in the differential diagnosis of bilateral facial palsy.

2024-02-01·Mayo Clinic proceedings. Innovations, quality & outcomes

A Practical Guide to Identify Patients With Multifocal Motor Neuropathy, a Treatable Immune-Mediated Neuropathy.

Review

作者: Jeffrey A Allen ; Amy E Clarke ; Thomas Harbo

Multifocal motor neuropathy (MMN) is a rare immune-mediated motor neuropathy characterized by asymmetric weakness that preferentially affects distal upper limb muscles. The clinical features of MMN may be difficult to differentiate from motor neuron disease. Other conditions that may be mistaken for MMN include inclusion body myositis, chronic inflammatory demyelinating polyradiculoneuropathy, hereditary neuropathy with liability to pressure palsy, focal neuropathies, and radiculopathies. A key distinguishing electrophysiologic feature of MMN is the motor nerve conduction block located at noncompressible sites. MMN is a treatable neuropathy; therefore it is important that primary care physicians are aware of the features of the disease to identify potential patients and make referrals to a neuromuscular specialist in a timely manner. This review provides an overview of the disease, highlights key differential diagnoses, and describes available treatment options for patients with MMN.

项与包涵体肌炎相关的新闻（医药）

2024-03-13

·PRNewswire

Study shows improved hand function using Carbonhand

STOCKHOLM, March 13, 2024 /PRNewswire/ -- Today, a study on Improved physical function using a power-enhancing glove in persons with Inclusion Body Myositis was presented at the Global Conference on Myositis in Pittsburgh, USA. The preliminary results show increased hand function and improved physical function for people with impaired hand function during use of Carbonhand. Inclusion body myositis (IBM) is an autoimmune disease that primarily affects skeletal muscles with reduced muscle strength and endurance as characteristic symptoms. People with IBM experience challenges in many areas of their lives. Gripping and holding objects as well as fine-motor activities are major parts of the challenges they face. Individuals with advanced IBM have difficulties holding utensils, gripping a glass to drink, holding a toothbrush, dressing, and undressing as well as many other activities of daily living requiring grip. The study aimed to investigate if a power-enhancing glove is feasible to use in persons with IBM. Data was collected during The Myositis Association's (TMA) patient conference in September 2023. The study was open to people with idiopathic inflammatory myopathies who perceived hand weakness. The analysis carried out is based on people with IBM. To assess the degree of impairment, Physical function (IBM-Patient Reported Outcome Upper Extremity Function Scale (IBM-PRO), IBM-Functional Rating Scale (IBM-FRS)), pain (numeric rating scale), and grip strength (Jamar) were measured. The study included 40 persons with IBM that had reduced grip strength (kg) (md;range) (3.75;1.3-10.7) and physical function (IBM-FRS 20;2-38, IBM-PRO 23;1-44). The participants selected three activities that they perceived as difficult. The participants performed the activities and rated their ability to perform the chosen activities on a 5-point scale (0 = "unable to do", 4= "without any difficulty"), first without the glove and then upon using the glove. After testing the glove, the participants answered a series of open-ended questions regarding their perception of the glove. The result All activities were perceived as easier to perform with the glove. The conclusion is that people with IBM can perform activities in daily living more independently when using Carbonhand as an assistive device. The three most selected activities, with pre-and post-glove ratings, are shown in Table 1. In the open-ended questions, participants documented that the glove would be beneficial for use in everyday tasks, lifting objects, grocery shopping, stabilizing the hand, and would increase independence. Table 1. Measures on difficulty in chosen activities without and with the glove (0="unable to do", 4="without any difficulty"). About the study The study is initiated by Karolinska University Hospital, Stockholm, Sweden, in collaboration with Louisiana State University and Tulane University Schools of Medicine, New Orleans, United States, Washington University School of Medicine, St. Louis, United States, The Ohio State University College of Medicine, Department of Pediatrics, Columbus, United States, Deutsche Gesellschaft für Muskelkranke e.V.", DGM, Taunusstein, Germany, Spierziekten Nederland (Dutch patient association for NMD), Rotterdam, The Netherlands, The Swedish Rheumatism Association, Stockholm, Sweden, and Bioservo AB, Stockholm, Sweden. About Carbonhand Carbonhand is a medical device in the form of a grip-enhancing glove that enables people with impaired hand function, like IBM, to regain the ability to use their hands. Sensors in the glove send signals to a sophisticated control system that activates motors that pull on artificial tendons sewn into the glove, creating a natural and dynamic grip. Several studies with more than 300 participants show that people with impaired hand function get a sustained and strong grip with Carbonhand, improving the user's ability to perform activities of daily living. For more information, please contact Annika Rydgård, Head of Clinical Projects and Market Access at Bioservo AB Phone: +46 70 440 41 71 Email: [email protected] Mikael Wester, Marketing Director at Bioservo AB Phone: +4670 721 12 80 Email: [email protected] About Bioservo Bioservo AB is a world-leading company in wearable muscle-strengthening systems for people who need extra strength and endurance. Our innovative products and systems are designed to improve the quality of life for our users and make them feel safe and independent. The company has a unique global position in soft active exoskeletons for the hand, which give people back the ability to manage their everyday lives and become independent and able to perform their tasks while maintaining health. Bioservo AB is a Swedish limited company headquartered in Kista, north of Stockholm.For more information, please visit This information was brought to you by Cision The following files are available for download: SOURCE Bioservo AB

临床结果

2024-02-18

·药智网

“全球药企一哥”的新下注方向

GLP-1领域的无敌之姿，也让礼来和诺和诺德登上了全球前二大市值药企，两者市值分别为7189.2亿美元、5493.95亿美元。更可怕的地方在于，“礼诺”正在不断的迭代和丰富自己的GLP-1布局，举措不仅包括广开新适应症、开发双&三靶点更强效果的分子、开发不同剂型的GLP-1药物及BD组合疗法伙伴。在投资者对于GLP-1资产市值上限和空间踌躇之时，新的减重伴生投资机会又在哪里？近期以来，礼来通过以19.25亿美元收购Versanis、投资BioAge Labs并计划联用其核心产品开展二期临床这两个动作，揭示了“全球药企一哥”全新的代谢领域下注方向：降脂增肌。01循环减重危害引发的全新需求众所周知，GLP-1减重药最大的软肋是“停药反弹”和“需长期服药”，对于利用GLP-1药物“循环减重”或者“间歇性用药”的患者人群十分不友好。对于GLP-1药物停药反弹想再次减重的患者来说，减重时除了失去脂肪还失去了肌肉，而体重反弹时他们恢复的只是脂肪；长此以往，“循环减肥”将渐进的改变这类人群的身体构成，身体的脂肪含量会越来越高，肌肉将越来越少。正因GLP-1类药物存在这类局限性，如何更高质量的减肥成了时下的热门研发领域。那么，肌肉流失的危害有多大？肌肉组织不仅支撑人类个体的日常运动，还起到帮助人体吸收营养物质并代谢掉体内的废物等功能。肌肉流失除了带来日常活动及体运动能力的下降，还会来带代谢改变、骨质疏松风险增加和免疫功能下降等危害。上述危害可能代表增加各类疾病的患病的风险，仅以肌肉的承重能力对应潜在疾病而言，当肌肉流失严重时，可能会发生如子宫脱垂、直肠脱垂等疾病，若流失的是心脏肌肉，还可能出现心肺功能减弱、心肺衰竭等危急情况。02百花齐放趋势的增肌减脂靶点降脂增肌作为新一代减肥药物或伴侣的研发方向，全球在研的靶点并不在少数，包括肌肉生长抑制素、雄激素受体调节剂、代谢调控加速器等，本文重点聚焦礼来系已经重点下注肌肉生长抑制素和艾帕素领域（ActRII受体和apelin受体靶点）。肌肉生长抑制素（MSTN）是一种限制骨骼肌然蛋白质（ActRII是MSTN主要受体），部分研究表明：其较高活性能够抑制骨骼肌的增长（研究表明敲除MSTN基因的小鼠肌肉质量增加25-30%），过去一直是神经肌肉疾病中治疗脊髓性肌萎缩症（SMA）的重要研究方向。图片来源：太平洋证券近年来，MSTN抑制剂的研发正好与目前减重药物的缺陷形成“互补”的曙光。一方面，MSTN抑制剂可能影响代谢过程，有助于调节能量平衡和代谢；另一方面，MSTN抑制剂对增加肌肉质量可能有帮助，可增加能量消耗进而有助于减少人体脂肪，达到此消彼长的目的。艾帕素（Apelin）是一种因运动而释放分泌的多肽，它通过与骨骼肌、心脏、和中枢神经系统的相互作用调节新陈代谢，调节新陈代谢并促进肌肉再生。BioAge的研究显示，人的一生中，总体Apelin水平会逐渐下降，而Apelin水平较高的人具有更强的身体功能和更长的寿命。从全球相关靶点研发进度看，MSTN抑制剂有较多临床在研产品，但核心适应症以肌肉萎缩相关适应症为主；而Apelin受体激动剂全球进入临床阶段的分子较少，BioAge的Azelapra进度领先。靶向肌肉生长抑制素疗法不完全统计图片来源：吉满生物礼来收购的Versanis靶向ActRII受体抑制剂Bimagrumab已经收获了非常积极的数据。据Versanis早前公布的48周二期临床针对2型糖尿病的超重或肥胖患者数据显示，相比安慰剂，尽管Bimagrumab治疗组的体重虽只下降了6.5%，造成患者约22%脂肪含量的丢失，并且增加4.5%的无脂体重。更重要的是，相比一般的GLP-1药物，Bimagrumab治疗组患者停止治疗12周内并未观察到体重的增加。而另一边礼来投资的BioAge，在一项227名65岁及以上的老年人的早期临床试验表明：Apelin受体激动剂Azelaprag可预防老年人的肌肉萎缩。从Bimagrumab到Azelaprag两款产品布局，我们可以看到礼来迭代、揽全的多点出击思维，但前者为单抗，后者为小分子，也考虑到了未来患者的依从性需求。03国产分子的机会相对于火热的减重，降脂增肌这样新兴而差异化的领域在国内显得更加的“先进而有价值”。目前从全球来看，ActRII和apelin两个靶点的竞争格局十分良好，尽管前者在研相关药物较多，但适应症以血液病、肺动脉高压、癌症为主，表现形式以ActRIIA/B融合蛋白为主；真正进入临床研究的、有计划以肥胖为适应症的ActRII抗体，仅有Versanis/礼来的Bimagrumab和来凯医药的LAE102；后者而言，前面提到BioAge的Azelapra可能是唯一一个进入临床的apelin激动剂。图片来源：太平洋证券对于国内Biotech来凯医药而言（不止于某家公司，而是针对ActRII靶点开发后来者），LAE102是存在较大突围机会的，原因有几个：1）礼来收购的Bimagrumab原研为诺华公司，原本针对一种罕见的肌肉萎缩疾病（散发性包涵体肌炎）治疗的中后期临床失败，转而进行减重适应症的研究（后Versanis从诺华手中收购）。也就是说，原本该药物并非以减重适应症为前期研发导向，后来me better分子有很大优化空间；2）Bimagrumab在安全性上也有优化空间，诺华2021年在JAMA发表的Bimagrumab临床数据显示：其核心不良事件是轻度腹泻(41%vs 11%)和肌肉痉挛(41%vs 3%)，尤其是首次给药后腹泻频率最高，后逐渐减少。3）另外针来凯医药的LAE102，其创始人吕博为Bimagrumab的共同发明者，可能对该靶点有更深的理解，或者对改良该靶点的管线有更强的优势。除了来凯医药之外，翰森药业也留意到了激活素（ActRII）受体靶点带来的广谱疾病治疗的机会。2021年12月翰森药业以2000万美金加高达1.705亿美元里程碑从Keros引入KER-050，该产品是一种“工程化的配体捕获体”，由经修饰的TGF-β受体（即激活素受体IIA型）配体结合区域与人源抗体的Fc区域融合而成，用于治疗骨髓增生异常综合征（MDS）和骨髓纤维化患者血细胞减少等领域患者。对于国内的创新药企业来说，减重药“伴侣”管线是能够获得MNC补全代谢领域布局的热门方向，也是全新的方向，存在巨大的机会。结语：华创医药从基于肌肉萎缩的抗衰治疗需求、消费者对于塑型的医美需求等分析指出，增肌本身便是有望和减肥相媲美的巨大蓝海市场；而从现已发现的ActRII、apelin等靶点潜力来看，随着癌症、肌肉萎缩疾病、肺动脉高压和代谢等适应症治疗潜力的逐步兑现，上述的展望并非是一句空话。来源 | 瞪羚社（药智网获取授权转载）撰稿 | Kris.责任编辑 | 八角声明：本文系药智网转载内容，图片、文字版权归原作者所有，转载目的在于传递更多信息，并不代表本平台观点。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间删除。商务合作 | 张武龙 13368443108（同微信）阅读原文，是昨天最受欢迎的文章哦

并购临床2期

2024-01-19

·创鉴汇

2023年生物医药领域最活跃机构投向何处？

▎药明康德内容团队编辑创新是生物医药行业发展的源动力。拥有平台研发能力、技术转化能力的创新药公司一直受到资本的青睐。众多投资公司如奥博资本、RA Capital Management（以下简称“RA Capital”)、Alexandria Venture Investments等持续活跃于生物医药领域投资。其中，RA Capital在2023年的表现尤为活跃。2023年，RA Capital至少投资了24家创新药企业，总投资金额超过25亿美元。对RA Capital2023年投资生物医药公司进行分析，发现：抗体药物为投资重点，获融资的新分子研发公司中，有8家公司研发抗体，其中双功能抗体研发公司Bicara Therapeutics一年内获得B轮及C轮两轮投资。同时，抗肿瘤药物为关注重点，被投资公司中13家布局研发抗肿瘤药物。# Aiolos Bio完成2.45亿美元A轮融资2023年10月24日，Aiolos Bio成立并完成了2.45亿美元A轮超额认购。Aiolos Bio是一家临床阶段生物医药公司，旨在满足罹患呼吸系统疾病和炎症性疾病患者的未竟医疗需求。此次超额认购的A轮融资由Atlas Venture、Bain Capital Life Sciences、Forbion和Sofinnova Investments共同领投，RA Capital追加了投资。2023年8月，Aiolos Bio从恒瑞医药获得了AIO-001在大中华地区以外的全球开发和商业化独家权益，AIO-001成为这家公司唯一一条产品管线。AIO-001是一种抗胸腺基质淋巴细胞生成素（TSLP）单克隆抗体，由于其药效具差异性、半衰期长，每年只需给药两次，为潜在“best-in-class“疗法。公司将继续推进其主要候选药物AIO-001在中重度哮喘患者中的2期临床试验，同时积极评估其他开发机会。# Mariana Oncology完成1.75亿美元B轮融资2023年9月7日，Mariana Oncology宣布完成1.75亿美元B轮融资。Mariana Oncology是一家新型放射性药物研发公司，专注于开创一类基于肽的靶向放射性药物。本次融资由Deep Track Capital和Forbion共同领投。初始投资者Atlas Venture、Access Biotechnology和RA Capital，以及新投资者Nextech Invest、Surveyor Capital和礼来公司也参与其中。该公司的放射性药物由经过合理设计的的偶联物组成，可释放α或β放射性核素有效载荷，能更好地穿透实体肿瘤，并含优化的高辐射活性剂量，而不会产生与化疗和毒素相关的副作用。该公司候选药物MC-339是一种肽类小分子，经改造后携带同位素锕（actinium）有效载荷，拟治疗小细胞肺癌。# Bicara Therapeutics完成1.65亿美元C轮融资 2023年12月12日，Bicara Therapeutics宣布完成1.65亿美元C轮融资。Bicara Therapeutics是一家专注于开发潜在“first-in-class”生物制品的临床阶段的生物技术公司，旨在将精准的靶向治疗和强大的肿瘤调节剂结合在一起。此次融资由Red Tree Venture Capital和RA Capital共同领投，Red Tree Venture Capital的负责人Krishna Polu博士、RA Capital Management的合伙人Jake Simson博士和F-Prime Capital的合伙人Ketan Patel博士将加入公司董事会。公司的双功能抗体能够将免疫调节有效载荷直接递送至肿瘤微环境，以增强免疫细胞活性，具有提供持久疗效的潜力。其主要候选产品BCA101是一种潜在“first-in-class”的EGFR/TGF-β陷阱双功能抗体，它的一端可以与癌细胞表面的EGFR受体结合，另一端是TGF-β陷阱。TGF-β在构建具有免疫抑制能力的肿瘤微环境中起到重要作用，通过捕获TGF-β，这款疗法可能改变肿瘤微环境，帮助增强免疫细胞的抗癌活性，目前正在进行临床1/1b期试验。据悉，本轮融资资金将用于进一步推进公司核心药物管线的研发。# Abcuro完成1.55亿美元B轮融资2023年8月17日，Abcuro宣布完成1.55亿美元B轮融资，获得的资金将主要用于完成潜在“first-in-class”抗体疗法ABC008的注册性2/3期临床试验。该轮融资由Redmile Group和贝恩资本生命科学基金（Bain Capital Life Sciences）共同领投。新投资者和现有投资者都参与其中，包括RA Capital, Samsara BioCapital, 赛诺菲风投（Sanofi Ventures）等投资机构。ABC008是一种潜在“first-in-class”的抗杀伤细胞凝集素样受体G1（KLRG1）单克隆抗体，能够选择性地消灭高细胞毒性T细胞，同时保留幼稚T细胞、调节性T细胞和中枢记忆T细胞。ABC008旨在治疗由高细胞毒性T细胞介导的疾病，包括包涵体肌炎（IBM）、T细胞大颗粒淋巴细胞白血病（T-LGLL）和成熟T细胞恶性肿瘤。美国FDA和欧洲药品管理局（EMA）已授予ABC008用于治疗IBM的孤儿药资格。# CG Oncology完成1.05亿美元超额认购融资 2023年8月2日，CG Oncology完成1.05亿美元的超额认购融资。本轮融资由Foresite Capital和TCGX共同领投，新投资者Aviity Partners、BVF Partners和Janus Henderson Investor，以及现有投资者RA Capital等投资机构也参与其中。CG Oncology在2010年由Paul DeRidder博士创立，是一家溶瘤免疫治疗公司，专注于为膀胱癌患者开发可以保留膀胱的疗法。公司的现任首席执行官为Arthur Kuan先生，他入选了知名行业媒体Endpoints News发布的生物医药40岁以下新一代领导者榜单（The 20 under 40 in Biopharma）。从研发管线来看，公司的主要候选药物cretostimogene grenadenorepvec（CG0070）是一种膀胱内给药的溶瘤病毒疗法，基于一种改造的5型腺病毒（Ad5）骨架，包括一个肿瘤特异性启动子，和一个粒细胞-巨噬细胞集落刺激因子（GM-CSF）转基因。# Alentis Therapeutics完成1.05亿美元C轮融资 2023年4月13日，Alentis Therapeutics宣布完成1.05亿美元C轮融资，本轮融资由Jeito Capital、Novo Holdings A/S和RA Capital领投。Alentis Therapeutics是一家以Claudin-1（CLDN1）为标靶开发实体瘤和纤维化突破性疗法的公司。公司正在推进其用于治疗癌症的主要候选药物ALE.F02的临床2期研究和治疗纤维化疾病的主要候选药物ALE.C04的临床1期研究。同时，本轮融资还将助力开发其CLDN1平台，推进抗体偶联药物（ADC）和双特异性抗体的研发。其CEO Roberto Iacone博士曾任罗氏（Roche）罕见病研究全球负责人。# Convergent Therapeutics完成A轮融资 2023年5月3日，Convergent Therapeutics宣布完成9000万美元A轮融资，本轮融资由OrbiMed和RA Capital Management领投。Convergent专注于开发治疗前列腺癌和其他癌症的下一代放射性药物疗法。公司的主要候选产品CONV01-α是一种与锕-225（Ac-225）结合的单克隆抗体，专为与前列腺特异性膜抗原（PSMA）结合而设计。锕-225是一种放射性α粒子发射器。CONV01-α的一个关键功能特性是，一旦与PSMA结合，它就会被内化，将其强大的放射性有效成分直接送入前列腺癌细胞，同时极大限度地降低对周围健康组织的损害。CONV01-α有望成为获批用于前列腺癌治疗的Ac-225放射性抗体。读者们请星标⭐创鉴汇，第一时间收到推送免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转发/复制至其他平台。转发授权请在「创鉴汇」微信公众号留言联系我们。更多数据内容推荐点击“在看”，分享创鉴汇健康新动态

放射疗法临床2期引进/卖出